Enrolling by invitationPHASE1, PHASE2NCT05577312
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
Studying Beta-thalassemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bioray Laboratories
- Principal Investigator
- Xiaochen Wang, PhDBioray Laboratories
- Intervention
- BRL-101(drug)
- Enrollment
- 39 enrolled
- Eligibility
- 3-35 years · All sexes
- Timeline
- 2022 – 2027
Study locations (4)
- Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
- The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- Xiangya Hospital of Central South University, Changsha, Hunan, China
- Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China
Collaborators
First Affiliated Hospital of Guangxi Medical University · Xiangya Hospital of Central South University · Chinese Academy of Medical Sciences · Nanfang Hospital, Southern Medical University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05577312 on ClinicalTrials.govOther trials for Beta-thalassemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07215975A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle EastBristol-Myers Squibb
- ENROLLING BY INVITATIONNCT07055503Use of the Hemanext One® Hypoxic Red Blood Cell Storage System for Transfusion in Thalassemia PatientsUniversity Research Institute for the Study of Genetic & Malignant Disorders in Childhood
- RECRUITINGNANCT07207577Evaluation of Physiological and Psychological Factors Involved in Exercise Intolerance in Patients With β-TTDCentre Hospitalier Metropole Savoie
- ENROLLING BY INVITATIONNCT06717932A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 InjectionCorrectSequence Therapeutics Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT06364774ALS20-101 Lentiviral Gene Therapy for Beta ThalassemiaChildren's Hospital of Philadelphia
- ENROLLING BY INVITATIONNCT06685536A Long-term Follow-up Study in Participants Who Received CS-101CorrectSequence Therapeutics Co., Ltd
- RECRUITINGPHASE1NCT06772766A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemiaMabwell (Shanghai) Bioscience Co., Ltd.
- RECRUITINGNANCT06734520Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemiaGuangzhou Women and Children's Medical Center